Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
What dose contraints do use for the pulmonary artery and vein when treating with a lung lesion with SBRT?
Related Questions
How does metaplastic thymoma histology impact your decision regarding adjuvant radiation?
How do you talk with your patients regarding radiographic expectations on surveillance CT after lung SBRT?
Can palliative radiation be used to treat recurrent malignant pleural effusion in NSCLC?
Do you recommend consolidation immunotherapy after SBRT or surgery and chemo for T1-T2N0 SCLC?
Do you use an LAD constraint in the setting of BID thoracic radiation for SCLC?
What target expansions do you use when treating with 60 Gy in 15 fractions for the lung?
Do more fractionated regimens reduce severe toxicity over SBRT in patients with ILD and early-stage NSCLC?
In resected N2 NSCLC, what nodal pathologic characteristics prompt you to recommend PORT?
Would the presence of an SVC stent affect your decision to offer BID vs once-daily chemoradiation for SCLC?
Would you give durvalumab consolidation to a patient with stage III NSCLC with an STK11 mutation?
